What are the recommended pharmacologic treatments for an adult with seasonal or perennial allergic rhinitis, and how do second‑generation antihistamines, intranasal corticosteroids, leukotriene receptor antagonists, and first‑generation antihistamines compare?

Recommended Pharmacologic Treatments for Allergic Rhinitis

First-Line Treatment: Intranasal Corticosteroids

Intranasal corticosteroids are the single most effective medication class for treating seasonal and perennial allergic rhinitis in adults and should be initiated immediately as monotherapy. 1, 2, 3

Why Intranasal Corticosteroids Are Superior

• Intranasal corticosteroids outperform all other medication classes for controlling the four cardinal symptoms: nasal congestion, rhinorrhea, sneezing, and nasal itching. 1, 4
• They are more effective than oral antihistamines for both nasal symptoms (mean difference -0.86 on Total Nasal Symptom Score) and ocular symptoms (mean difference -0.36), with clinically meaningful improvements in quality of life (mean difference -0.88 on RQLQ). 4
• Intranasal corticosteroids are markedly superior to leukotriene receptor antagonists (mean difference -1.05 on Total Nasal Symptom Score), which should not be used as primary therapy. 1, 5
• All FDA-approved intranasal corticosteroids (fluticasone propionate, mometasone furoate, budesonide, triamcinolone) demonstrate equivalent clinical efficacy; selection can be based on availability and patient preference. 2

Dosing and Administration

• Adults and adolescents ≥12 years: 2 sprays per nostril once daily (200 mcg total). 2
• Onset of action: Symptom relief begins within 3-12 hours, though maximal benefit requires several days to weeks of continuous use. 2, 3
• Proper technique: Use the contralateral hand (opposite hand for each nostril) to direct spray away from the nasal septum—this reduces epistaxis risk by fourfold. 2

Safety Profile

• No systemic effects: Intranasal corticosteroids at recommended doses do not suppress the hypothalamic-pituitary-adrenal axis, affect growth in children, or increase risk of cataracts or glaucoma. 2
• Most common side effect: Epistaxis (nasal bleeding), typically mild blood-tinged secretions occurring in 4-20% of patients, minimized by proper spray technique. 2

---

Second-Line: Add Intranasal Antihistamine for Inadequate Response

For moderate-to-severe allergic rhinitis not adequately controlled with intranasal corticosteroid alone, add an intranasal antihistamine (azelastine) rather than an oral antihistamine. 1, 2

Evidence for Combination Therapy

• The combination of fluticasone propionate + azelastine produces >40% relative improvement in nasal symptom scores compared with either agent alone. 1
• In clinical trials, the combination showed the greatest symptom reduction: placebo (-2.2 to -3.03), azelastine alone (-3.25 to -4.54), fluticasone alone (-3.84 to -5.1), and fluticasone + azelastine (-5.31 to -5.7) on a 24-point Total Nasal Symptom Score scale. 1
• Intranasal antihistamines are more effective than oral antihistamines for seasonal allergic rhinitis (mean difference -0.47 on Total Nasal Symptom Score). 4

Common Side Effects

• Dysgeusia (bitter taste) is the most common adverse event, occurring in 2.1-13.5% of patients. 1
• Somnolence is minimal (0.4-1.1%), similar to placebo rates. 1

---

Oral Antihistamines: Limited Role

Oral antihistamines should NOT be routinely added to intranasal corticosteroids, as they provide no additional benefit for nasal symptoms. 2

When to Consider Oral Antihistamines

• For mild intermittent allergic rhinitis: Second-generation oral antihistamines (cetirizine, fexofenadine, desloratadine, loratadine) may be used as monotherapy. 3
• Second-generation agents are strongly preferred over first-generation antihistamines (diphenhydramine, chlorpheniramine), which cause sedation, impairment, and worsen sleep architecture. 6
• Intranasal antihistamines are superior to oral antihistamines for both symptom control and quality of life. 4, 7

---

Leukotriene Receptor Antagonists: Not Recommended

Leukotriene receptor antagonists (montelukast) should not be used as primary therapy for allergic rhinitis. 1, 2

Evidence Against Leukotriene Antagonists

• They are significantly less effective than intranasal corticosteroids for daytime nasal symptoms (standardized mean difference 0.41) and nighttime symptoms. 5
• They are equivalent to oral antihistamines but inferior to intranasal treatments. 5
• Even the combination of leukotriene antagonist + oral antihistamine is inferior to intranasal corticosteroids alone for nasal congestion. 5

---

First-Generation Antihistamines: Avoid

First-generation antihistamines (diphenhydramine, chlorpheniramine, brompheniramine) should not be used for allergic rhinitis. 6

Why First-Generation Agents Are Harmful

• They produce sedation, cognitive impairment, and reduced quality of life. 6
• They worsen sleep architecture despite causing drowsiness. 6
• The differences in safety between first- and second-generation antihistamines are larger than the differences among second-generation agents. 6

---

Treatment Algorithm

Step 1: Initial Therapy

• Start intranasal corticosteroid (fluticasone, mometasone, or budesonide) 2 sprays per nostril once daily. 1, 2, 3
• Counsel patient that full benefit requires 2 weeks of continuous use. 2
• Teach contralateral-hand spray technique to minimize epistaxis. 2

Step 2: Inadequate Response After 2-4 Weeks

• Add intranasal antihistamine (azelastine) to the intranasal corticosteroid. 1, 2
• Do NOT add oral antihistamines—they provide no additional nasal symptom benefit. 2

Step 3: Persistent Rhinorrhea Despite Combination Therapy

• Add ipratropium bromide 0.03% nasal spray (2 sprays per nostril 2-3 times daily) specifically for profuse clear nasal drainage. 2

Step 4: Severe Initial Congestion

• For patients with severe nasal congestion at presentation, consider a short 3-5 day course of topical decongestant (oxymetazoline) while initiating intranasal corticosteroid to improve drug delivery. 2
• Never exceed 3 days of decongestant use to avoid rebound congestion (rhinitis medicamentosa). 2

---

Common Pitfalls to Avoid

• Do not prescribe oral antihistamine + intranasal corticosteroid as initial therapy—intranasal corticosteroid monotherapy is equally effective and more cost-efficient. 2
• Do not delay intranasal corticosteroid initiation while awaiting allergy testing results; testing is reserved for patients who fail empiric therapy. 2
• Do not use leukotriene receptor antagonists as first-line treatment—they are markedly inferior to intranasal corticosteroids. 1, 5
• Do not prescribe first-generation antihistamines—they cause sedation and impairment without superior efficacy. 6
• Do not assume all intranasal corticosteroids are safe for young children—beclomethasone should be avoided in pediatrics due to growth suppression risk. 2

---

Comparative Effectiveness Summary

Treatment	Efficacy vs. Placebo	Comparative Effectiveness	Recommendation
Intranasal corticosteroids	Most effective for all 4 nasal symptoms [1,4]	Superior to oral antihistamines, intranasal antihistamines, and leukotriene antagonists [4,5]	First-line monotherapy [1,2,3]
Intranasal antihistamines	Effective for nasal symptoms [4]	Superior to oral antihistamines; inferior to intranasal corticosteroids [4]	Add-on to intranasal corticosteroid for inadequate response [1,2]
Oral second-generation antihistamines	Effective for mild symptoms [3]	Inferior to intranasal treatments [4]; no added benefit when combined with intranasal corticosteroid [2]	Only for mild intermittent disease [3]
Leukotriene receptor antagonists	Better than placebo [5]	Equivalent to oral antihistamines; markedly inferior to intranasal corticosteroids [5]	Not recommended as primary therapy [1,2]
First-generation antihistamines	Effective but sedating [6]	Cause sedation, impairment, and worsen sleep [6]	Avoid entirely [6]